These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36031904)

  • 1. Sleep Disturbances, Cognitive Status, and Biomarkers of Dementia.
    Zawar I; Mattos MK; Manning C; Quigg M
    J Alzheimers Dis; 2022; 89(4):1367-1374. PubMed ID: 36031904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sleep Disturbances Predict Cognitive Decline in Cognitively Healthy Adults.
    Zawar I; Mattos MK; Manning C; Patrie J; Quigg M
    J Alzheimers Dis; 2023; 92(4):1427-1438. PubMed ID: 36970907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between self-reported sleep quality and cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease.
    Durães J; Marques P; Novo AM; Facas J; Duro D; Lima M; Leitão MJ; Tábuas-Pereira M; Baldeiras I; Santana I
    Rev Neurol (Paris); 2023 Oct; 179(8):877-881. PubMed ID: 36914478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction of global small vessel disease burden and Alzheimer's disease pathologies do not change the independent association of amyloid-beta with hippocampal volume: A longitudinal study on mild cognitive impairment subjects.
    Yu M; Feng L; Zhao X; Huang Q; Xia N; Xia H; Wen C; Wang M; Zhu Z; Yang Y;
    Hippocampus; 2023 Nov; 33(11):1197-1207. PubMed ID: 37638636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.
    Pichet Binette A; Palmqvist S; Bali D; Farrar G; Buckley CJ; Wolk DA; Zetterberg H; Blennow K; Janelidze S; Hansson O
    Alzheimers Res Ther; 2022 Mar; 14(1):46. PubMed ID: 35351181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleep Disorders and Cognitive Aging Among Cognitively Impaired Versus Unimpaired Older Adults.
    Lee S; Nelson ME; Hamada F; Wallace ML; Andel R; Buxton OM; Almeida DM; Lyketsos C; Small BJ
    Gerontologist; 2024 May; 64(5):. PubMed ID: 37944004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sleep disturbances, cognitive decline, and AD biomarkers alterations in early Parkinson's disease.
    Zhong R; Gan C; Sun H; Zhang K
    Ann Clin Transl Neurol; 2024 Jul; 11(7):1831-1839. PubMed ID: 38764318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study.
    Reijs BLR; Vos SJB; Soininen H; Lötjonen J; Koikkalainen J; Pikkarainen M; Hall A; Vanninen R; Liu Y; Herukka SK; Freund-Levi Y; Frisoni GB; Frölich L; Nobili F; Rikkert MO; Spiru L; Tsolaki M; Wallin ÅK; Scheltens P; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(4):1387-1395. PubMed ID: 29036813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
    Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
    Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
    Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
    J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Montreal Cognitive Assessment in Mild Cognitive Impairment: Relationship with Cerebrospinal Fluid Biomarkers and Conversion to Dementia.
    Bernardes C; Lima M; Duro D; Silva-Spínola A; Durães J; Tábuas-Pereira M; Baldeiras I; Freitas S; Santana I
    J Alzheimers Dis; 2023; 96(3):1173-1182. PubMed ID: 37927268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
    Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H
    JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults.
    Trzepacz PT; Hochstetler H; Wang S; Walker B; Saykin AJ;
    BMC Geriatr; 2015 Sep; 15():107. PubMed ID: 26346644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient.
    Hsu CC; Wang SI; Lin HC; Lin ES; Yang FP; Chang CM; Wei JC
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.